IMDX Stock News & Catalysts

FEATURED

iMDx to Release Third Quarter Results on November 16, 2026

NASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report third quarter 2026 financial results after the market closes on

Summary

Nov 5, 2026, 7:00 AM ·Globe Newswire

RECENT

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the company’s

Oct 14, 2026, 8:00 AM ·Globe Newswire

iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings

NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health

Oct 12, 2026, 8:00 AM ·Globe Newswire

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference

NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth

Sep 2, 2026, 8:00 AM ·Globe Newswire

Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing

NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at

Aug 11, 2026, 4:05 PM ·Globe Newswire

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Discussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of substantive review in a timely mannerFavorable Medicare reimbursement policy issued in July

Aug 10, 2026, 4:05 PM ·Globe Newswire

iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference

NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on

Aug 4, 2026, 7:00 AM ·Globe Newswire

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejectionSerial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA)

Jul 23, 2026, 8:00 AM ·Globe Newswire

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's commercial strategy in transplant monitoringFinal policy establishes recurring testing baseline

Jul 16, 2026, 3:22 PM ·Globe Newswire

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58Recent studies advanced science of molecular diagnostic

Jun 29, 2026, 8:00 AM ·Globe Newswire

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation- NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc.,

Jun 22, 2026, 2:07 PM ·Globe Newswire

Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitorGraftAssure's industry-leading reference change value (time-point to time-point

Jun 16, 2026, 4:05 PM ·Globe Newswire

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA aloneGraftAssure™ assay doubles reliability of positive

Jun 11, 2026, 4:17 PM ·Globe Newswire

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specificallyMajor transplantation conference in Boston will create

Jun 9, 2026, 4:05 PM ·Globe Newswire

IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagementNortheast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial

May 13, 2026, 4:05 PM ·Globe Newswire

Insight Molecular Diagnostics Inc. IMDX · News